These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 23123020

  • 1. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease.
    Shinjo SK, de Moraes JC, Levy-Neto M, Aikawa NE, de Medeiros Ribeiro AC, Schahin Saad CG, Precioso A, Silva CA, Bonfá E.
    Vaccine; 2012 Dec 17; 31(1):202-6. PubMed ID: 23123020
    [Abstract] [Full Text] [Related]

  • 2. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
    Campos LM, Silva CA, Aikawa NE, Jesus AA, Moraes JC, Miraglia J, Ishida MA, Bueno C, Pereira RM, Bonfa E.
    Arthritis Care Res (Hoboken); 2013 Jul 17; 65(7):1121-7. PubMed ID: 23818263
    [Abstract] [Full Text] [Related]

  • 3. Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy.
    Guissa VR, Pereira RM, Sallum AM, Aikawa NE, Campos LM, Silva CA, Bonfá E.
    Clin Exp Rheumatol; 2012 Jul 17; 30(4):583-8. PubMed ID: 22931582
    [Abstract] [Full Text] [Related]

  • 4. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.
    Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, Duarte A, Miraglia JL, Timenetsky Mdo C, Viana VS, França IL, Bonfa E, Pereira RM.
    J Rheumatol; 2012 Jan 17; 39(1):167-73. PubMed ID: 22089462
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients.
    Aikawa NE, Trudes G, Campos LM, Pereira RM, Moraes JC, Ribeiro AC, Miraglia J, Timenetsky Mdo C, Bonfa E, Silva C.
    Lupus; 2013 Nov 17; 22(13):1394-8. PubMed ID: 24076765
    [Abstract] [Full Text] [Related]

  • 6. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis.
    Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E.
    Arthritis Care Res (Hoboken); 2013 Mar 17; 65(3):476-80. PubMed ID: 22949223
    [Abstract] [Full Text] [Related]

  • 7. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, França IL, Carvalho JF, Sampaio-Barros PD, Goncalves CR, Borba EF, Timenetsky Mdo C, Precioso AR, Duarte A, Bonfa E, Laurindo IM.
    Ann Rheum Dis; 2011 Dec 17; 70(12):2144-7. PubMed ID: 21859696
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
    Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, Chotpitayasunondh C.
    Vaccine; 2012 Feb 01; 30(6):1108-14. PubMed ID: 22178515
    [Abstract] [Full Text] [Related]

  • 9. Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome.
    Pasoto SG, Ribeiro AC, Viana VS, Leon EP, Bueno C, Neto ML, Precioso AR, Timenetsky Mdo C, Bonfa E.
    Vaccine; 2013 Apr 03; 31(14):1793-8. PubMed ID: 23395584
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, Arad U, Brill A, Paran D, Levartovsky D, Wigler I, Caspi D, Mandelboim M.
    Arthritis Care Res (Hoboken); 2011 Jul 03; 63(7):1062-7. PubMed ID: 21425247
    [Abstract] [Full Text] [Related]

  • 11. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H.
    Vaccine; 2012 Nov 06; 30(48):6864-70. PubMed ID: 22989690
    [Abstract] [Full Text] [Related]

  • 12. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis.
    Aikawa NE, Campos LM, Goldenstein-Schainberg C, Saad CG, Ribeiro AC, Bueno C, Precioso AR, Timenetsky Mdo C, Silva CA, Bonfá E.
    Scand J Rheumatol; 2013 Nov 06; 42(1):34-40. PubMed ID: 22992045
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y, Yang Z, Li L, Ye D, Wu H, Fu R, Zhao S, Wang Y, Zhou R, Chen R.
    Jpn J Infect Dis; 2011 Nov 06; 64(3):190-4. PubMed ID: 21617301
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct 06; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 15. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.
    Vaccine; 2011 Sep 16; 29(40):6888-93. PubMed ID: 21803100
    [Abstract] [Full Text] [Related]

  • 16. Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population--a practical observation.
    Sun F, Zhang Y, Tian D, Zheng M, Liu L, Zhang R, Dai Z, Chen J, Li T, Lu H.
    Vaccine; 2011 Sep 02; 29(38):6527-31. PubMed ID: 21767595
    [Abstract] [Full Text] [Related]

  • 17. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.
    Vaccine; 2012 Jul 13; 30(33):5009-18. PubMed ID: 22658967
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea.
    Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.
    Vaccine; 2011 Jan 10; 29(3):523-7. PubMed ID: 21055502
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.
    Vaccine; 2012 Jan 20; 30(5):936-40. PubMed ID: 22138210
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.
    Miossi R, Fuller R, Moraes JC, Ribeiro AC, Saad CG, Aikawa NE, Miraglia JL, Ishida MA, Bonfa E, Caleiro MT.
    Clinics (Sao Paulo); 2013 Jan 20; 68(2):129-34. PubMed ID: 23525305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.